Other Cytokinetics Soars on Aficamten Trial Results but Faces Unusual Shareholder Deficit by ytools September 5, 2025 September 5, 2025 Cytokinetics just shocked the market with a 31% stock surge after unveiling trial results for its heart drug aficamten. The medicine outperformed the current standard treatment, showing real promise for … Read more 0 FacebookTwitterWhatsappTelegram